Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Brain Diseases × enzalutamide × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 164 Neoplasm Metastasis 20 Prostatic Neoplasms, Castration-Resistant 19 Breast Neoplasms 18 Neoplasms 15 Metastatic Castration Resistant Prostate Cancer 9 Prostate Cancer Metastatic 7 Metastatic Castration-Resistant Prostate Cancer 7 Triple Negative Breast Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Pancreatic Neoplasms 4 Metastatic Castration-resistant Prostate Cancer 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Prostate Adenocarcinoma 3 Colorectal Neoplasms 3 Castration-resistant Prostate Cancer 3 Carcinoma, Hepatocellular 3 Adenocarcinoma 3 mCRPC 2 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Recurrence 2 Ovarian Neoplasms 2 Non-metastatic Castration-resistant Prostate Cancer 2 Metastatic Hormone-sensitive Prostate Cancer 2 Metastatic Hormone Sensitive Prostate Cancer 2 Metastatic Castration-resistant Prostate Cancer (mCRPC) 2

Interventions

XENP 1595 2 Cancer Vaccines 2 Bevacizumab 2 Adjuvants, Immunologic 2 veliparib 1 glutathione pegylated liposomal doxorubicin 1 etoposide phosphate 1 enzalutamide 1 elacestrant 1 binimetinib 1 abemaciclib 1 Trastuzumab 1 Tissue Banks 1 Temozolomide 1 Radiotherapy 1 Radiosurgery 1 Radiation 1 RAD1901 1 Patient Discharge 1 PF-07284890 1 Midazolam 1 Etoposide 1 Dasatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04290611 2023-04-13

VENDY

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Brain Diseases, Epilepsy, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡